Cellebrite DI Ltd. develops software and services for legally sanctioned investigations. Listed on the Nasdaq under the ticker CLBT, the company assists public and private sector organizations in collecting, reviewing, analyzing, and managing digital data from smartphones, computers, cloud accounts, and other sources. From what I see, investors track Cellebrite because it occupies a specialized and expanding niche: as digital evidence becomes central to virtually every investigation, demand for purpose-built forensic and investigative software continues to grow across law enforcement, corporate security, and government agencies worldwide.
Cellebrite was founded in 1999 and is headquartered in Petah Tikva, Israel, with a global customer footprint across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. The company began trading publicly on the Nasdaq on August 31, 2021. Its business model centers on a digital intelligence platform that supports the full investigative lifecycle, from accessing and extracting data to reviewing, analyzing, and sharing digital evidence. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company's core offering is Inseyets, digital forensics software used to collect and review evidence from a wide range of digital sources. Alongside it, Cellebrite's Guardian suite provides evidence management, collaboration, and case-management capabilities, including AI-powered analytics tools such as Pathfinder. Through its acquisition of Corellium, Cellebrite also offers mobile vulnerability research and penetration testing capabilities under the Corellium Falcon and Viper product lines. These tools are used in investigations involving child exploitation, homicide, counterterrorism, organized crime, human trafficking, border control, corporate security, and financial crimes, including those involving cryptocurrency.
Revenue comes primarily from software licenses and subscriptions, along with professional services such as training, certification, and advanced support. Cellebrite serves federal, state, and local agencies as well as corporate and enterprise customers, giving it a diversified public- and private-sector client base. Within the digital forensics market, Cellebrite competes with companies such as Nuix, Oxygen Forensics, and PenLink, among others, and is widely regarded as one of the most established names in mobile and digital forensics.
Cellebrite attracts investor attention for several long-term reasons. First, its market position in digital forensics is reinforced by deep technical expertise, a broad product portfolio, and longstanding relationships with government and law-enforcement customers, which can create switching costs and recurring revenue through subscriptions and support contracts. Second, the company's business model benefits from durable secular demand: the volume of digital evidence continues to grow as devices, cloud services, and encrypted data proliferate, driving ongoing need for investigative software. Third, Cellebrite's expansion into AI-powered analytics and evidence management reflects a broader shift toward automating investigative workflows, a trend that could support long-term growth beyond its traditional forensics tools.
The company's financial profile has shown steady revenue growth, reflecting consistent demand from its core government and enterprise customers. Investors also view Cellebrite's international reach and its mix of software and services as factors that help diversify its revenue base across regions and customer types. One thing that stands out is how these elements combine to support a resilient operation in a specialized field.
Investing in Cellebrite carries several considerations. The company relies heavily on government and public-sector budgets, which can be subject to procurement cycles, funding constraints, and shifting political priorities. Its operations are also sensitive to regulatory and legal scrutiny, given the powerful nature of its investigative technology and ongoing debates over privacy and the use of digital forensics tools. Additionally, Cellebrite faces competition from both established forensics providers and emerging analytics vendors, and technological disruption, particularly around device encryption and security updates, could affect the effectiveness of its products. As an Israel-headquartered company, Cellebrite is also exposed to regional geopolitical and currency risks. Investors should weigh these factors alongside the company's growth potential. I'm watching this closely as part of any broader portfolio review.
In my view, incorporating modern AI-driven platforms into the research process can help surface relevant data points and comparisons efficiently. I have found that reviewing stocks through Tickeron's AI Screener allows for quick filtering based on technical indicators, fundamentals, and industry trends, which aligns well with evaluating names like CLBT in the context of their peers.
Cellebrite DI Ltd. has established itself as a specialized leader in digital intelligence, providing the software that law enforcement and enterprises rely on to manage ever-growing volumes of digital evidence. Its combination of forensic extraction tools, evidence management, and AI-powered analytics, supported by a global customer base and recurring software revenue, makes it a distinctive name in the technology sector. While government dependence and regulatory sensitivity remain important considerations, Cellebrite's role at the intersection of cybersecurity, forensics, and artificial intelligence keeps it relevant for investors evaluating long-term opportunities in digital investigation technology.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLBT's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 214 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 214 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
The 10-day moving average for CLBT crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLBT advanced for three days, in 221 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for CLBT moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 30 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 61 cases where CLBT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLBT as a result. In 68 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for CLBT turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 45 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
CLBT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CLBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.815) is normal, around the industry mean (16.188). P/E Ratio (51.875) is within average values for comparable stocks, (45.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.427) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (103.301).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ComputerCommunications